<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335852</url>
  </required_header>
  <id_info>
    <org_study_id>1771-101-008</org_study_id>
    <nct_id>NCT03335852</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD</brief_title>
  <acronym>PINE</acronym>
  <official_title>Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and to characterize the systemic pharmacokinetics of free
      and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly
      intravitreal injections of abicipar in Japanese patients with neovascular age-related macular
      degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">October 8, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Serum Concentration (CMax) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Concentration Immediately before Next Dose (Ctrough) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve from Zero to the End of the Dosing Interval &quot;tau&quot; (AUC0-tau) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUC0-inf) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Anti-abicipar Antibodies</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity using an Eye Chart</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Change from Baseline in Full Ophthalmic Exam Findings [i.e. Slit Lamp Exam, Intraocular Pressure (IOP) Measurements, Funduscopic Exam]</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in General Physical Condition as Measured through General Physical Exam</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Changes from Baseline in Vital Signs (Blood Pressure, Pulse Rate, ECG)</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Change from Baseline in Clinically Relevant Laboratory Values (Serum Chemistry, Hematology, Urinalysis)</measure>
    <time_frame>Baseline to Week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Abicipar pegol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg administered to the study eye by intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abicipar pegol</intervention_name>
    <description>Abicipar pegol 2 mg administered to the study eye by intravitreal injection</description>
    <arm_group_label>Abicipar pegol</arm_group_label>
    <other_name>AGN-150998</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female patients

          -  Presence of active subfoveal and/or juxtafoveal choroidal neovascularization (CNV)
             secondary to age-related macular degeneration (AMD)

        Exclusion Criteria:

          -  History of or active periocular, ocular, or intraocular infection

          -  Previous use of ocular anti-angiogenic therapy within 1 month (ranibizumab), 6 weeks
             (pegaptanib), or 2 months (bevacizumab and aflibercept) of Day 1 for the treatment of
             neovascular AMD or neovascular eye diseases other than AMD

          -  Macular hemorrhage that involves the center of fovea in the study eye

          -  Previous use of verteporfin photodynamic therapy (PDT) or previous therapeutic
             radiation in the region

          -  Treatment with ocular corticosteroid injections or implants within 6 months in the
             study eye

          -  History or evidence of eye surgery: Pars plana vitrectomy, Submacular surgery or other
             surgical interventions for AMD, Incisional glaucoma surgery or Cataract or refractive
             surgery within the last 3 months

          -  AMD or neovascular eye diseases other than AMD in the non-study eye that require
             anti-VEGF treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Sutherland</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimura Eye and Internal Medicine Hospital</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0029</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashi Dream Clinic</name>
      <address>
        <city>Tennouji-ku</city>
        <state>Osaka</state>
        <zip>543-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takeuchi Eye Clinic</name>
      <address>
        <city>Taito-ku</city>
        <state>Tokyo</state>
        <zip>111-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souseikai Hakata Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com.</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‚ÄêCTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2017</study_first_submitted>
  <study_first_submitted_qc>November 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

